Emery Pharma highlights the formation of nitrosamines during secondary or tertiary amine API interactions with trace nitrites in acidic extraction solvents.
Public source
Publisher name
Public post
False-positive nitrosamines are one of the most frustrating traps in bioanalytical chemistry, and they happen more often than drug discovery teams might realize. When se…
Company
Emery Pharma
Finding innovative solutions for scientific problems to help save lives and save the planet
- Industry
- Research Services
- Location
- Alameda, US
- Company size
- 11–50 employees
About Emery Pharma
Emery Pharma (EP) (emerypharma.com) is a FDA registered/inspected, DEA licensed, and cGMP/GLP compliant full service contract research laboratory specializing in microbiology & cell-biology testing, medicinal chemistry, analytical chemistry, and bio-analytical services. EP is located in Alameda, CA, at the heart of San Francisco Bay area. We have been supporting clients both locally and globally. We have deep expertise in drug development and support clients from early preclinical all the way to Phase 3 clinical program. Our Bioanalytical Chemistry team utilizes the state of the art LCMS-MS instrument to unravel the targeted compounds in blood, plasma, skin, etc- We provide assistance with R&D method development, validation, method transfer and analytical services. Medicinal Chemistry: Our team has expertise in diverse therapeutic areas covers all aspects of medicinal chemistry, from strategic planning to hit evaluation and validation to lead optimization and pre-clinical development. Analytical Separation Chemistry: Utilizing NMR, LC-MS, HPLC, GC-MS. Microbiology: Spectrum of Antibacterial and Antifungal Activity, Biofilm Profiling, Resistance Profiling, Cytotoxicity Testing, Microscopy Services, Tissue Efficacy Modeling
See moreLatest activity
Latest activity from Emery Pharma
3 signals
Research & Knowledge
Emery Pharma performed 2D NMR experiments on its 400 MHz Bruker NMR to map out the precise atomic connections of compounds and provide structural analysis alongside decision-ready reports.
Research & Knowledge
Emery Pharma ran a side-by-side bridging study comparing a standard Triple Quadrupole mass spectrometer (Agilent 6470) and a High-Resolution Orbitrap system (Exploris 240) to evaluate analytical performance across trace impurities.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
PI Health Sciences Ltd
PI Health Sciences Ltd identified a Nitrosamine Drug Substance-Related Impurity (NDSRI) in an API during sample preparation, highlighting the importance of analytical services and PharmaTesting.
Research & Knowledge
Sygnature Discovery
Sygnature Discovery published a new case study demonstrating how impurity isolation, HR-MS/MS, and multidimensional NMR can be combined to move from an unknown peak to definitive structural confirmation.
Research & Knowledge
Sygnature Discovery North America
Sygnature Discovery North America published a new publication in Bioconjugate Chemistry by Allan Jordan, Stuart Best, and Josh Greally exploring medicinal chemistry considerations shaping the next generation of targeted ADC payloads.
Research & Knowledge
Frontage Laboratories, Inc
Frontage Laboratories, Inc developed a comprehensive MIST assessment integrating in vitro and in vivo assays to meet FDA and ICH regulatory expectations.
Research & Knowledge
QPS Holdings, LLC